|
Engels P., Szolek A., Hörner S., Syrigos G.V., Hebbel K., Schmidtke M., Zhou M., Mateo-Tortola M., Schönfeld C., Stefanczyk S.A., Wolter K., Babaei S., Schindler M., Claassen M., Dauch D., Zender L., Tapía-Abellán A., Weber A.N.R. Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence. Cancer Immunology, Immunotherapy. July 2025. 74. 10.1007/s00262-025-04060-w
AÑO: 2025; IF: 5.1
|
40374812
|
Morva A, Arroyo AB, Andreeva L, Tapia-Abellan A, Luengo-Gil G. Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review. Front Immunol. 2025 Jun 12;16:1615760. doi: 10.3389/fimmu.2025.1615760. eCollection 2025. PubMed PMID: 40574837; PubMed Central PMCID: PMC12198237.
AÑO: 2025; IF: 5.9
|
|
Molina-Lopez C, Hurtado-Navarro L, Garcia CJ, Angosto-Bazarra D, Vallejo F, Tapia-Abellan A, Marques-Soares JR, Vargas C, Bujan-Rivas S, Tomas-Barberan FA, Arostegui JI, Pelegrin P. Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1beta production. Nat Commun. 2024 Feb 6;15(1):1096. doi: 10.1038/s41467-024-44990-0. PubMed PMID: 38321014; PubMed Central PMCID: PMC10847128.
AÑO: 2024; IF: 15.7
|
|
Martin-Sanchez F, Penin-Franch A, Angosto-Bazarra D, Tapia-Abellan A, Compan V, Pelegrin P. Measuring NLR Oligomerization III: Detection of NLRP3 and NLRC4 Complex by Bioluminescence Resonance Energy Transfer. Methods Mol Biol. 2023;2696:93-103. doi: 10.1007/978-1-0716-3350-2_6. PubMed PMID: 37578717.
AÑO: 2023
|
|
Weber ANR, Tapia-Abellan A, Liu X, Arostegui JI, Pelegrin P, Welzel T, Kuemmerle-Deschner JB. Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply. Rheumatology (Oxford). 2023 May 2;62(5):e168-e169. doi: 10.1093/rheumatology/keac718. No abstract available. PubMed PMID: 36562561.
AÑO: 2023; IF: 4.7
|